OTC$LIANY
Lianbio-Adr · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
LianBio-Adr's financial performance was reported for Q2 2022 and a corporate update was provided.
LianBio reported a net loss of $42.4 million for the second quarter of 2022, with research and development expenses at $28.6 million and general and administrative expenses at $14.6 million. The company's cash balance at the end of the quarter was $349.4 million, expected to fund operations into the second half of 2024. Key milestones included completing enrollment in the China Phase 3 trial of mavacamten and submitting NDAs for mavacamten in Singapore and infigratinib in Hong Kong.
- Completed enrollment in China Phase 3 trial of mavacamten with topline data expected mid-2023.
- Submitted mavacamten New Drug Application (NDA) in Singapore.
- Submitted infigratinib NDA in Hong Kong.
- Cash balance of $349.4 million at the end of second quarter 2022 with runway into the second half of 2024.
Headline financials
Revenue & EPS history
Lianbio-Adr · Revenue · Quarterly
$0
Forward guidance
LianBio anticipates several key milestones in 2022 and 2023, focusing on advancing its clinical programs and preparing for potential commercialization.
Tailwinds
- Topline data from the Phase 3 EXPLORER-CN trial of mavacamten is expected in mid-2023.
- A Phase 3 study in Chinese patients with Demodex blepharitis for TP-03 is expected to begin in the second half of 2022.
- Dosing patients in Nanobiotix’s global Phase 3 NANORAY-312 clinical trial of NBTXR3 is expected to begin in the second half of 2022.
- A Phase 1 monotherapy clinical trial of BBP-398 in advanced solid tumors is expected to begin in the fourth quarter of 2022.
- A Phase 1 clinical trial of BBP-398 in combination with an EGFR-inhibitor in non-small cell lung cancer is expected to begin in the first half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q2 2022
+8.4%
Avg return
Earnings day
+8.4%
Avg return
5 days after
-3.1%
Avg return
30 days after
77%
10 / 13 earnings
Positive
+17.7%
Q4 2020
Best reaction
-4.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | -2.2% | -6.7% | -7.4% | |
| Q3 2023 | +0.7% | +1.5% | +4.2% | |
| Q2 2023 | +2.7% | +0.0% | -9.7% | |
| Q1 2023 | -4.1% | +4.6% | +17.7% | |
| Q4 2022 | -1.2% | +17.4% | +18.0% | |
| Q3 2022 | +17.5% | +38.9% | +7.1% | |
| Q2 2022 | +11.1% | -1.5% | -3.0% | |
| Q1 2022 | +9.3% | +29.8% | +28.4% | |
| Q4 2021 | +3.9% | +26.1% | +7.3% | |
| Q2 2021 | +17.7% | +0.4% | -17.3% | |
| Q3 2021 | +17.7% | +0.4% | -17.3% | |
| Q4 2020 | +17.7% | +0.4% | -17.3% | |
| Q1 2021 | +17.7% | -2.4% | -50.4% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro